Clinical Trial: Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

U.S., Feb. 1 -- ClinicalTrials.gov registry received information related to the study (NCT06803030) titled 'Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms' on Jan. 27.

Brief Summary: A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.

Study Start Date: Feb. 01

Study Type: INTERVENTIONAL

Condition: Ureteral Stent-Related Symptom

Intervention: DRUG: Tamsulosin Hydrochloride 0.4 mg

placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily

DRUG: Solifenacin Succinate 5 mg

placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily

DRUG: Mirabegron 25 mg...